The efficacy of Silybum marianum (L.) Gaertn. (silymarin) in the treatment of type II diabetes: a randomized, double-blind, placebo-controlled, clinical trial.
about
Identification of isosilybin a from milk thistle seeds as an agonist of peroxisome proliferator-activated receptor gammaCoadjuvants in the Diabetic Complications: Nutraceuticals and Drugs with Pleiotropic EffectsNatural Products to Counteract the Epidemic of Cardiovascular and Metabolic DisordersHerbal medicine for the management of polycystic ovary syndrome (PCOS) and associated oligo/amenorrhoea and hyperandrogenism; a review of the laboratory evidence for effects with corroborative clinical findingsTherapeutic phytogenic compounds for obesity and diabetesSilymarin in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled TrialsEngineered silybin nanoparticles educe efficient control in experimental diabetesDrug-botanical interactions: a review of the laboratory, animal, and human data for 8 common botanicals.Therapeutics role of olive fruits/oil in the prevention of diseases via modulation of anti-oxidant, anti-tumour and genetic activity.Effect of oral cinnamon intervention on metabolic profile and body composition of Asian Indians with metabolic syndrome: a randomized double -blind control trial.Plant-Derived Compounds Targeting Pancreatic Beta Cells for the Treatment of Diabetes.Nutritional supplements and their effect on glucose control.A Randomized Clinical Trial Study: Anti-Oxidant, Anti-hyperglycemic and Anti-Hyperlipidemic Effects of Olibanum Gum in Type 2 Diabetic Patients.Silybin and the liver: from basic research to clinical practice.Review of clinical trials evaluating safety and efficacy of milk thistle (Silybum marianum [L.] Gaertn.).In vivo efficacy study of milk thistle extract (ETHIS-094™) in STAM™ model of nonalcoholic steatohepatitisComparative effects of silymarin and vitamin E supplementation on oxidative stress markers, and hemoglobin levels among patients on hemodialysis.Efficacy of lifestyle changes in subjects with non-alcoholic liver steatosis and metabolic syndrome may be improved with an antioxidant nutraceutical: a controlled clinical studyEffect of silymarin in diabetes mellitus patients with liver diseases.Optimization and single-laboratory validation of a method for the determination of flavonolignans in milk thistle seeds by high-performance liquid chromatography with ultraviolet detection.Herbal therapies for type 2 diabetes mellitus: chemistry, biology, and potential application of selected plants and compoundsFuture directions for research on Silybum marianum for cancer patients.Prophylactic Administration of Silybin Ameliorates L-Arginine-Induced Acute Pancreatitis.Herb-drug interactions: challenges and opportunities for improved predictions.Trends in publication of evidence-based Traditional Iranian medicine in endocrinology and metabolic disorders.Phytotherapy in diabetes: Review on potential mechanistic perspectives.The therapeutic potential of milk thistle in diabetes.Silymarin Activates c-AMP Phosphodiesterase and Stimulates Insulin Secretion in a Glucose-Dependent Manner in HIT-T15 Cells.A Novel Natural Product, KL-21, Inhibits Proliferation and Induces Apoptosis in Chronic Lymphocytic Leukemia Cells.Non-alcoholic Fatty Liver Disease: Beneficial Effects of Flavonoids.Silymarin: A Novel Natural Agent to Restore Defective Pancreatic β Cells in Streptozotocin (STZ)-induced Diabetic Rats.Silymarin alleviates hepatic oxidative stress and protects against metabolic disorders in high-fat diet-fed mice.Silymarin and dimercaptosuccinic acid ameliorate lead-induced nephrotoxicity and genotoxicity in rats.The battered β-cell: usual suspects and guilt by association.Beneficial effects of silibinin against the progression of metabolic syndrome, increased oxidative stress, and liver steatosis in Psammomys obesus, a relevant animal model of human obesity and diabetes.A newly developed silymarin nanoformulation as a potential antidiabetic agent in experimental diabetes.Berberis aristata/Silybum marianum fixed combination on lipid profile and insulin secretion in dyslipidemic patients.The Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-Part 2: Management and special groups.Addition of silymarin to renin-angiotensin system blockers in normotensive patients with type 2 diabetes mellitus and proteinuria: a prospective randomized trial.Effects of an Herbal Combination on Glycemic Control and Lipid Profile in Diabetic Women: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.
P2860
Q24567657-2C06BB27-DCA1-41B8-B970-6B35F30BC866Q26741423-F21EA021-6854-4CBE-A4FE-CA47A71B72DCQ26747523-C36B7CE2-9295-4614-BFC4-5A2D67FC53A4Q27002469-9E124A7E-90AC-4E7E-98A0-17DA85516AB7Q27004043-1229E326-7E44-406A-A9B1-188FF731720DQ28071012-86F10BF8-D384-412E-9131-406755F33F35Q28540351-F3CAAD55-17B8-472B-AD24-2221ACDC43EFQ33509452-BAB415BE-E6B4-4DC8-AE9E-61BB03C906ECQ33756187-CB59595D-B6BC-4F7F-AA8B-3C649190CE3EQ33791991-67B26715-C2B2-4DD5-A0D0-32710A769760Q34045439-634FB61D-9CFE-40F8-AA8F-F79159A82B1CQ34162991-0F6CE638-DEDB-4CBC-B5B3-45B09973CD1EQ34256210-F9248255-E7E4-4916-A7B0-C4D61D4305D7Q34629765-41D27BA4-9DE1-464D-B0AB-3A133B43451FQ34634353-393D816C-4154-4C67-B2E9-61B66E8CB92EQ34727822-3B51F02D-B198-448A-9609-0FC9FD6CEC5CQ35126099-A4B4B431-97F8-49BD-8B4B-1B1A653601E8Q35175904-E427C2CF-6FFA-42DC-BD0A-5E454C004C63Q35411480-E4B472AB-E0AB-4547-9CFB-A749648946C5Q36073650-171F8380-E217-4C41-B6CA-C08AD62888C2Q36801780-17F5E73A-C5E1-42E1-84DA-C503FDAD217EQ36840447-D8338B9F-5BD0-4A6D-BA07-4D22C3E12CDAQ37351003-7DF7A18B-AA34-4130-88BC-8B02EED15F21Q37603890-8DCB5074-3B24-4EC0-92EB-EBB7B16923A5Q37685328-29C0D398-9DD4-41C4-845A-A38FC71DC6BFQ38205765-5E05413C-551C-482E-8A97-F3B072DEE05DQ38268147-C4AE85CB-3AC8-433D-8510-1212A1390CA7Q38726251-0E4DC050-E58A-4897-8642-24D61AA27D3CQ38840067-04155DCF-7ACF-438C-8108-8242D053BF6DQ38866384-3A749208-CFBD-4800-B55F-B8D1DD274EEEQ39096833-894559D7-B661-4AC9-8485-84B952E1983DQ40116615-5AE1A4A5-BF41-4ADE-875C-59C048957C51Q40832115-C787970A-F3E8-43E6-86C4-079E4C1F2529Q43004895-521B8084-8079-43F3-9EC7-8636E173F7C7Q43427762-C2BC4AE9-F6C9-436C-85D0-4F209AE9CF41Q46788863-DBC587F0-D879-4B78-89AB-023082FEF97DQ47716717-009B0292-6E90-4794-A893-ED00E724CD68Q48152092-59D6A051-C5BE-4115-9DCE-192832EA159EQ49835011-E8CE161E-EC77-4E49-B244-B17F0B9A95A8Q49926482-A1F7FCF8-7C92-492E-8E76-EADED4E4AE71
P2860
The efficacy of Silybum marianum (L.) Gaertn. (silymarin) in the treatment of type II diabetes: a randomized, double-blind, placebo-controlled, clinical trial.
description
2006 nî lūn-bûn
@nan
2006 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
The efficacy of Silybum marian ...... bo-controlled, clinical trial.
@ast
The efficacy of Silybum marian ...... bo-controlled, clinical trial.
@en
The efficacy of Silybum marian ...... bo-controlled, clinical trial.
@nl
type
label
The efficacy of Silybum marian ...... bo-controlled, clinical trial.
@ast
The efficacy of Silybum marian ...... bo-controlled, clinical trial.
@en
The efficacy of Silybum marian ...... bo-controlled, clinical trial.
@nl
prefLabel
The efficacy of Silybum marian ...... bo-controlled, clinical trial.
@ast
The efficacy of Silybum marian ...... bo-controlled, clinical trial.
@en
The efficacy of Silybum marian ...... bo-controlled, clinical trial.
@nl
P2093
P356
P1476
The efficacy of Silybum marian ...... bo-controlled, clinical trial.
@en
P2093
B Larijani
B Radjabipour
H Fakhrzadeh
H Fallah Huseini
Mohsin Raza
P304
P356
10.1002/PTR.1988
P577
2006-12-01T00:00:00Z